大活络丸联合艾拉莫德治疗类风湿性关节炎的临床研究

目的探讨大活络联合艾拉莫德治疗类风湿性关节炎的临床疗效。方法选取2017年8月—2019年8月在河南中医药大学第三附属医院治疗的类风湿性关节炎患者96例,随机分为对照组和治疗组,每组各48例。对照组患者口服艾拉莫德片,25 mg/次,2次/d。治疗组在对照组基础上口服大活络丸,1丸/次,2次/d。两组连续治疗14 d。观察两组临床疗效,同时比较治疗前后两组炎性因子白细胞介素6(IL-6)、IL-8、肿瘤坏死因子-α(TNF-α)和C反应蛋白(CRP)水平,及类风湿因子、红细胞沉降率、类风湿DAS28评分和不良反应。结果治疗后,对照组总有效率为81.25%,明显低于治疗组的95.83%(P<0.05)。治疗后,两组IL-6、IL-8、TNF-α、CRP均显著降低(P<0.05),治疗组IL-6、IL-8、TNF-α、CRP均低于对照组患者(P<0.05)。治疗后,两组类风湿因子、红细胞沉降率、类风湿DAS28评分、压痛关节数、肿胀关节数均显著降低(P<0.05)。治疗后,治疗组类风湿因子、红细胞沉降率指标均低于对照组(P<0.05),治疗组患者类风湿DAS28评分、压痛关节数、肿胀关节数均低于对照组(P<0.05)。对照组不良反应发生率12.00%,明显高于治疗组的8.33%(P<0.05)。结论大活络丸联合艾拉莫德治疗类风湿关节炎临床效果明显优于艾拉莫德治疗,具有一定的临床推广应用价值。

Clinical study on Dahuoluo Pills combined with iguratimod in treatment of rheumatoid arthritis

Objective To investigate the curative effect of Dahuoluo Pills combined with iguratimod in treatment of rheumatoid arthritis. Methods Patients(96 cases) with rheumatoid arthritis in Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from August 2017 to August 2019 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Iguratimod Tablets, 25 mg/time, twice daily. Patients in the treatment group were po administered with Dahuoluo Pills on the basis of the control group, 1 pill/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the serum levels of IL-6, IL-8, TNF-α and CRP, the rheumatoid factor, erythrocyte sedimentation rate, rheumatoid DAS28 score and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.25%, which was significantly lower than 95.83% in the treatment group(P < 0.05). After treatment, IL-6, IL-8, TNF-α and CRP in two groups were significantly decreased(P < 0.05). The serum levels of IL-6, IL-8, TNF-α and CRP in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the rheumatoid factor, erythrocyte sedification rate, rheumatoid DAS28 score, the number of painful joints and the number of swollen joints were significantly decreased in both groups(P < 0.05). After treatment, the rheumatoid factor, erythrocyte sedimentation rate in the treatment group were significantly lower than those in the control group(P < 0.05), the rheumatoid DAS28 score, tenderness joint number, swelling joint number in the treatment group were significantly lower than those in the control group(P < 0.05). During the treatment, the adverse reactions rate in the control group was 12.00%, which was significantly higher than 8.33% in treatment the group(P < 0.05). Conclusion The therapeutic effect of Dahuoluo Pills combined with iguratimod in treatment of rheumatoid arthritis is significantly better than that of single treatment of iguratimod, which has a certain clinical application value.